AB
Abbott Laboratories
ABT · NYSE
$108.32 -0.43% (-$0.47)
1M +0.48%
Market Cap $188.2B
P/E Ratio 34.70x
Div. Yield 2.28%
ROE 10.52%
Bulios Fair Price
$73.35
32.3% downside
Current Price
$108.32
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
38 /100
Fair P/E 34.70x
EV/EBITDA 21.70x
P/S 4.04x
Growth
27 /100
Declining EPS growth 1.65%
Rev. growth 0.51%
FCF growth 1.78%
Profitability
86 /100
Strong Gross margin 56.80%
Net margin 11.65%
Op. margin 17.03%
Quality
40 /100
Average ROIC 6.07%
ROE 10.52%
ROA 4.97%
Debt
68 /100
Low Debt/Equity 0.64x
Current ratio 1.38x
Int. coverage 12.56x
Stability
69 /100
Stable Beta 0.58x
Rev. volatility 7.67%
EPS volatility 98.26%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABT
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford
Employees
115,000
Headquarters
Abbott Park
Upcoming events
21 OCT
Earnings
Upcoming earnings report